NCT05179486 Molecular Epidemiology of Biliary Tree Cancers
| NCT ID | NCT05179486 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Cholangiocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2017-09-25 |
| Primary Completion | 2027-02-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2017-09-25 with a primary completion date of 2027-02-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree cancers. Establishing biomarkers models from patients may help doctors to further understand how biliary tree cancer is affected by different treatments, and why some people's cancer responds differently than others.
Eligibility Criteria
Inclusion Criteria: * Pathologically or radiologically confirmed diagnosis of CGC or GBC * With or without prior radiation or chemotherapy * All United States of America (USA) and non USA residents * No age, gender, or racial restriction * Healthy control with no current or history of cancer * Healthy controls are USA and non USA residents * Healthy controls are matched to the cases in age (5 years), gender, and race * Healthy controls are friends and spouses of patients with other than gastro-intestinal (GI) cancers * Chronic Liver Disease (CLD) controls with no current or history of cancer * CLD controls are USA and non USA residents * CLD controls are frequency matched to CGC cases by age (5 years), gender, and race * CLD controls are patients are diagnosed with or without liver biopsy (core or fine needle aspiration) * CLD controls must not have evidence liver cancer diagnosis by computed tomography (CT) or magnetic resonance imaging (MRI) Exclusion Criteria: * None
Contact & Investigator
Manal M Hassan
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT05179486 clinical trial?
This trial is open to participants of all sexes, studying Cholangiocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05179486 currently recruiting?
Yes, NCT05179486 is actively recruiting participants. Contact the research team at mhassan@mdanderson.org for enrollment information.
Where is the NCT05179486 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT05179486 clinical trial?
NCT05179486 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Manal M Hassan at M.D. Anderson Cancer Center. The trial plans to enroll 1,500 participants.